Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00266877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
Study identification
- NCT ID
- NCT00266877
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 172 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Dec 31, 2008
- Completion
- Dec 31, 2008
- Last update posted
- Apr 12, 2018
2005 – 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Midwestern Regional Medical Center | Zion | Illinois | 60099 | — |
| Massachusetts General Hospital, Yawkey Center for Outpatient Care | Boston | Massachusetts | 02114 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Memorial Sloan-Kettering | New York | New York | 10021 | — |
| Carolinas Hematology-Oncology Associates | Charlotte | North Carolina | 28203 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6868 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
Recently updated Carcinoma, Non-Small-Cell Lung trials
Other public records listing Carcinoma, Non-Small-Cell Lung. Sorted by last update posted; newest first. Not a recommendation.
- NCT07586202: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Recruiting
- NCT07339176: Intratumoral N17350 in Advanced Solid Tumors Recruiting
- NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
- NCT03381274: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study Active, not recruiting
- NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer Recruiting
- NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00266877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00266877 live on ClinicalTrials.gov.